title: [An evaluation of the hypolipidemic effects of lovastatin in primary hypercholesterolemia. A multicenter study].
abstract: In the multicenter trial, the hypolipidemic efficacy and adverse event profile of lovastatin were estimated in 294 patients with primary hypercholesterolemia. The mean baseline (on placebo) lipid and lipoprotein values were: total serum cholesterol (TC) 313 mg/dl, triglycerides (TG) 168 mg/dl, low density lipoprotein cholesterol (LDL-C) 235 mg/dl, high density lipoprotein cholesterol (HDL-C) 44.9 mg/dl. Lovastatin was begun with 20 mg/day, the dose being doubled after 4 and 8 weeks if the target reduction of TC < 200 mg/dl was not reached at those moments. At the end of the treatment the mean TC decreased by 29.5% (p) as compared with the baseline level, TG by 14% (p). The normal target level of TC was reached in 106 patients (36%), the borderline levels (200-240 mg/dl) in 123 (42%), high TC (240 mg/dl) remained in 65 patients (22%). LDL-C decreased by 38% (p), HDL-C increased by 7.8% (p), whereas LDL-C/HDL-C ratio decreased by 40% (p). The treatment was well tolerated by patients: mild clinical side effects were noticed in 2.7% of patients and asymptomatic transient deviations of laboratory tests in 8.2%. The authors conclude about high hypolipidemic efficacy and low adverse event profile of lovastatin in patients with primary hypercholesterolemia.
authors.forename: A A
authors.initials: AA
authors.lastname: Liakishev
authors.forename: V V
authors.initials: VV
authors.lastname: Kukharchuk
authors.forename: V N
authors.initials: VN
authors.lastname: Titov
authors.forename: E I
authors.initials: EI
authors.lastname: Volkova
authors.forename: V O
authors.initials: VO
authors.lastname: Konstantinov
authors.forename: B M
authors.initials: BM
authors.lastname: Lipovetskiĭ
authors.forename: I B
authors.initials: IB
authors.lastname: Soliternova
authors.forename: V A
authors.initials: VA
authors.lastname: Dudko
authors.forename: N V
authors.initials: NV
authors.lastname: Kanskaia
authors.forename: V A
authors.initials: VA
authors.lastname: Kryzhanovskiĭ
mesh_terms: D000328:Adult; D000368:Aged; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy; D013997:Time Factors; D014586:USSR
chemical_list: D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin
vernacular_title: Otsenka gipolipidemicheskikh éffektov lovastatina pri pervichnoĭ giperkholesterinemii. Mnogotsentrovoe issledovanie.